(HCA) HCA Healthcare - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NYSE (USA) | Market Cap: 83.975m USD | Total Return: -2.3% in 12m
Avg Turnover: 577M
EPS Trend: 99.1%
Qual. Beats: 0
Rev. Trend: 99.4%
Qual. Beats: 0
Warnings
Altman Z'' 0.58 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
HCA Healthcare, Inc. is a Nashville-based provider of comprehensive health care services, operating a diverse network of general and acute care hospitals, outpatient surgery centers, and emergency facilities across the United States. The companys infrastructure supports a full continuum of care, ranging from inpatient surgical and intensive care to diagnostic imaging, urgent care, and hospice services.
As a major player in the Health Care Facilities sub-industry, HCA utilizes a scale-driven business model that aims to capture market share through high-acuity service lines and geographic clusters. The sector is characterized by high fixed costs and significant regulatory oversight, where profitability often depends on favorable payor mixes and efficient facility utilization rates.
Reviewing historical valuation trends on ValueRay can provide further context on the companys long-term performance.
- Managed care contract negotiations determine commercial reimbursement rates and operating margins
- Inpatient volume growth and acuity levels drive hospital revenue per equivalent admission
- Labor cost inflation and nursing shortage impact hospital operating expenses and profitability
- Medicare and Medicaid reimbursement policy changes affect government-sourced revenue streams
- Strategic capital expenditure on outpatient facilities expands market share and patient access
| Net Income: 6.79b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 4.63 > 1.0 |
| NWC/Revenue: -4.20% < 20% (prev 3.67%; Δ -7.87% < -1%) |
| CFO/TA 0.21 > 3% & CFO 13.0b > Net Income 6.79b |
| Net Debt (50.7b) to EBITDA (15.7b): 3.24 < 3 |
| Current Ratio: 0.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (226.7m) vs 12m ago -9.14% < -2% |
| Gross Margin: 34.92% > 18% (prev 0.41%; Δ 3.45k% > 0.5%) |
| Asset Turnover: 126.0% > 50% (prev 119.7%; Δ 6.29% > 0%) |
| Interest Coverage Ratio: 5.28 > 6 (EBITDA TTM 15.7b / Interest Expense TTM 2.29b) |
| A: -0.05 (Total Current Assets 16.1b - Total Current Liabilities 19.3b) / Total Assets 61.5b |
| B: -0.10 (Retained Earnings -5.98b / Total Assets 61.5b) |
| C: 0.20 (EBIT TTM 12.1b / Avg Total Assets 60.6b) |
| D: -0.09 (Book Value of Equity -5.98b / Total Liabilities 64.4b) |
| Altman-Z'' = 0.58 = B |
| DSRI: 0.96 (Receivables 11.3b/11.1b, Revenue 76.4b/71.6b) |
| GMI: 1.17 (GM 34.92% / 40.90%) |
| AQI: 0.99 (AQ_t 0.19 / AQ_t-1 0.20) |
| SGI: 1.07 (Revenue 76.4b / 71.6b) |
| TATA: -0.10 (NI 6.79b - CFO 13.0b) / TA 61.5b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of June 02, 2026, the stock is trading at USD 370.96 with a total of 2,165,563 shares traded.
Over the past week, the price has changed by -5.86%,
over one month by -14.35%,
over three months by -30.29% and
over the past year by -2.28%.
HCA Healthcare has received a consensus analysts rating of 4.04. Therefore, it is recommended to buy HCA.
- StrongBuy: 13
- Buy: 2
- Hold: 9
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 511 | 37.7% |
P/E Trailing = 13.0396
P/E Forward = 12.4844
P/S = 1.0993
P/B = 291.3383
P/EG = 1.1414
Revenue TTM = 76.4b USD
EBIT TTM = 12.1b USD
EBITDA TTM = 15.7b USD
Long Term Debt = 39.5b USD (from longTermDebt, last quarter)
Short Term Debt = 8.53b USD (from shortTermDebt, last quarter)
Debt = 51.7b USD (from shortLongTermDebtTotal, last quarter) + Leases 1.82b
Net Debt = 50.7b USD (calculated: Debt 51.7b - CCE 940.0m)
Enterprise Value = 135b USD (84.0b + Debt 51.7b - CCE 940.0m)
Interest Coverage Ratio = 5.28 (Ebit TTM 12.1b / Interest Expense TTM 2.29b)
EV/FCF = 16.99x (Enterprise Value 135b / FCF TTM 7.93b)
FCF Yield = 5.88% (FCF TTM 7.93b / Enterprise Value 135b)
FCF Margin = 10.38% (FCF TTM 7.93b / Revenue TTM 76.4b)
Net Margin = 8.89% (Net Income TTM 6.79b / Revenue TTM 76.4b)
Gross Margin = 34.92% ((Revenue TTM 76.4b - Cost of Revenue TTM 49.7b) / Revenue TTM)
Gross Margin QoQ = 14.98% (prev 41.90%)
Tobins Q-Ratio = 2.19 (Enterprise Value 135b / Total Assets 61.5b)
Interest Expense / Debt = 4.42% (Interest Expense 2.29b / Debt 51.7b)
Taxrate = 18.80% (430.0m / 2.29b)
NOPAT = 9.80b (EBIT 12.1b * (1 - 18.80%))
Current Ratio = 0.83 (Total Current Assets 16.1b / Total Current Liabilities 19.3b)
Debt / Equity = -8.20 (negative equity) (Debt 51.7b / totalStockholderEquity, last quarter -6.30b)
Debt / EBITDA = 3.24 (Net Debt 50.7b / EBITDA 15.7b)
Debt / FCF = 6.40 (Net Debt 50.7b / FCF TTM 7.93b)
Total Stockholder Equity = -3.12b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.21% (Net Income 6.79b / Total Assets 61.5b)
RoE = 237.5% (Net Income TTM 6.79b / Total Stockholder Equity 2.86b)
RoCE = 28.50% (EBIT 12.1b / Capital Employed (Equity 2.86b + L.T.Debt 39.5b))
RoIC = 19.33% (NOPAT 9.80b / Invested Capital 50.7b)
WACC = 6.10% (E(84.0b)/V(136b) * Re(7.65%) + D(51.7b)/V(136b) * Rd(4.42%) * (1-Tc(0.19)))
Discount Rate = 7.65% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.56 | Cagr: -7.66%
[DCF] Terminal Value 77.97% ; FCFF base≈6.74b ; Y1≈7.72b ; Y5≈11.4b
[DCF] Fair Price = 542.2 (EV 171b - Net Debt 50.7b = Equity 120b / Shares 221.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 99.07 | EPS CAGR: 20.64% | SUE: 0.05 | # QB: 0
Revenue Correlation: 99.35 | Revenue CAGR: 7.93% | SUE: 0.12 | # QB: 0
EPS current Quarter (2026-06-30): EPS=7.38 | Chg30d=-1.27% | Revisions=-30% | Analysts=20
EPS next Quarter (2026-09-30): EPS=7.30 | Chg30d=+0.62% | Revisions=+18% | Analysts=20
EPS current Year (2026-12-31): EPS=30.20 | Chg30d=-0.39% | Revisions=-39% | GrowthEPS=+7.1% | GrowthRev=+3.9%
EPS next Year (2027-12-31): EPS=33.14 | Chg30d=-0.57% | Revisions=-17% | GrowthEPS=+9.7% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: -39%